1. Home
  2. COGT vs SNCY Comparison

COGT vs SNCY Comparison

Compare COGT & SNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • SNCY
  • Stock Information
  • Founded
  • COGT 2014
  • SNCY 1982
  • Country
  • COGT United States
  • SNCY United States
  • Employees
  • COGT N/A
  • SNCY N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • SNCY Air Freight/Delivery Services
  • Sector
  • COGT Health Care
  • SNCY Consumer Discretionary
  • Exchange
  • COGT Nasdaq
  • SNCY Nasdaq
  • Market Cap
  • COGT 555.6M
  • SNCY 644.3M
  • IPO Year
  • COGT 2018
  • SNCY 2021
  • Fundamental
  • Price
  • COGT $5.44
  • SNCY $11.58
  • Analyst Decision
  • COGT Buy
  • SNCY Buy
  • Analyst Count
  • COGT 6
  • SNCY 7
  • Target Price
  • COGT $15.20
  • SNCY $17.43
  • AVG Volume (30 Days)
  • COGT 1.2M
  • SNCY 864.4K
  • Earning Date
  • COGT 05-06-2025
  • SNCY 05-01-2025
  • Dividend Yield
  • COGT N/A
  • SNCY N/A
  • EPS Growth
  • COGT N/A
  • SNCY N/A
  • EPS
  • COGT N/A
  • SNCY 0.98
  • Revenue
  • COGT N/A
  • SNCY $1,090,905,000.00
  • Revenue This Year
  • COGT N/A
  • SNCY $6.72
  • Revenue Next Year
  • COGT N/A
  • SNCY $10.37
  • P/E Ratio
  • COGT N/A
  • SNCY $11.80
  • Revenue Growth
  • COGT N/A
  • SNCY 2.24
  • 52 Week Low
  • COGT $3.72
  • SNCY $8.10
  • 52 Week High
  • COGT $12.61
  • SNCY $18.59
  • Technical
  • Relative Strength Index (RSI)
  • COGT 56.27
  • SNCY 51.86
  • Support Level
  • COGT $4.80
  • SNCY $10.88
  • Resistance Level
  • COGT $4.99
  • SNCY $11.96
  • Average True Range (ATR)
  • COGT 0.31
  • SNCY 0.47
  • MACD
  • COGT 0.07
  • SNCY -0.02
  • Stochastic Oscillator
  • COGT 88.56
  • SNCY 34.14

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About SNCY Sun Country Airlines Holdings Inc.

Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.

Share on Social Networks: